To evaluate invivo safety and efficacy of a hair care formulation in terms of reduction in Hair loss - N/AP

Sahyadri Bio Labs Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Having androgenetic alopecia of class I-2 to I-4 according to Ludwig Scale for females and class II
•to III (including III, IIIA and IIIvertex) according to Norwood Hamilton Scale for males.

•Having naturally fair or white hair
•Having a dermatosis on the scalp
•aving history of any harmonal problem.
•Having surgery history on the scalp (micro transplants â?¦)
•Refusing the shaving of an area of the scalp of about 1.5 cmÂ², the first day of the study and several times during the study
•Having presented a factor inducing a telogen effluvium in the 3 months preceding the start of the study (important stress, high feverâ?¦)
•Presenting an acute or chronic general desease or pathology which could have an influence on hair
•endocrinopathy (diabetes, thyroidâ?¦), high blood pressure, renal problems, hepatic problems,
•known anaemia. Having contact allergy or atopic predisposition.
•Having history of medical/surgical events that may significantly affect the study outcome eg h/o
•typhoid or jaundice etc.

发起方

Sahyadri Bio Labs Pvt Ltd